The state of Texas currently has 44 active clinical trials seeking participants for Depression research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Effects of Exercise and Virtual Reality on Depression
Recruiting
This study is evaluating the effects of riding on a cycle ergometer while experiencing virtual reality to determine its effect on mood.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/24/2025
Locations: UTArlington, Arlington, Texas
Conditions: Symptoms of Depression
Dallas 2K: A Natural History Study of Depression
Recruiting
The primary objective of this initiative is to implement a prospective study that will allow us to identify and validate biosignatures of response to treatments for depression and depression outcome (using an integrated array of participant specific data: socio-demographic, lifestyle, clinical and behavioral assessments, fluid-based biomarkers, genomics, neuroimaging, EEG, and cell-based assays) in a longitudinal cohort of subjects with elevated symptoms of a depressive disorder. Symptom remiss... Read More
Gender:
ALL
Ages:
10 years and above
Trial Updated:
04/22/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Depression, Depression, Bipolar
Resilience in Adolescent Development
Recruiting
RAD is a 10-year natural history, longitudinal, prospective assessment study of a cohort of 2,500 participants (ages 10-24 years) that will help uncover the socio-demographic, lifestyle, clinical, psychological, and neurobiological factors that contribute to resilience among children, adolescents, and young adults at-risk for mood and anxiety disorders. As this is an exploratory study, we will assess a comprehensive panel of carefully selected participant specific parameters, including socio-dem... Read More
Gender:
ALL
Ages:
Between 10 years and 24 years
Trial Updated:
04/22/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Risk Assessment, Resilience, Psychological, Depression, Mood Disorders, Anxiety Disorders, Mental Health
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
Recruiting
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.
Gender:
ALL
Ages:
Between 22 years and 70 years
Trial Updated:
04/21/2025
Locations: University of Texas Southwestern Medical Center at Dallas, Dallas, Texas +2 locations
Conditions: Treatment Resistant Depression
RE104 Safety and Efficacy Study in Postpartum Depression
Recruiting
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
04/18/2025
Locations: Reunion Investigational Site, Austin, Texas +4 locations
Conditions: Postpartum Depression
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
Recruiting
This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major Depressive disorder (TRD) and will characterize the onset and durability of antidepressant effects of VLS-01-BU versus placebo.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/11/2025
Locations: InSite Clinical Research, DeSoto, Texas
Conditions: Treatment Resistant Depression
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
Recruiting
Suicide is the 10th leading cause of death for Americans of all ages and more people in the United States now die from suicide than die from car accidents. Although death by firearm remains the most common cause of suicide in the United States, an intentional overdose of substance usage such as prescription opioids accounts for over 5,000 suicides per year. In 2017, more than 70,000 drug overdose deaths occurred, making it the leading cause of injury-related death, and well over half (67.8%) inv... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/02/2025
Locations: The Menninger Clinic, Houston, Texas
Conditions: Substance Abuse, Suicide, Depression
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
Recruiting
Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: The University of Texas at Austin - Dell Medical School, Austin, Texas +6 locations
Conditions: Treatment Resistant Depression
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
Recruiting
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associate... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
03/24/2025
Locations: BioBehavioral Research of Austin /ID# 227076, Austin, Texas +11 locations
Conditions: Depression, Bipolar I Disorder
Wellness App for Sleep Disturbance in Hematological Cancer Patients
Recruiting
In a randomized controlled trial (RCT), the investigators will recruit participants to an 8-week "app-based wellness" intervention, followed by a 12-week follow-up period. The investigators will recruit a total of 276 self-declared Chronic Hematological Cancer (CHC) patients who (representative of age, race/ethnicity, and gender) will be on stable CHC pharmacologic therapy (if any), self-identify as sleep disturbed (\>5 on Pittsburgh Sleep Quality Index), do not have a sleep disorder diagnosis,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Mays Cancer Center at The University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Cancer, Sleep Disturbance, Anxiety, Depression, Inflammation, Fatigue
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression
Recruiting
The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD II) depression.
Gender:
ALL
Ages:
Between 25 years and 70 years
Trial Updated:
03/12/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Bipolar II Disorder, Depression, Bipolar, Suicidality
PCORI Comparative Effectiveness Study-Esketamine (Spravato) Vs. Ketamine-Equivalence Study
Recruiting
The purpose of this study is to compare the relative effectiveness, acceptability, and side effects of ketamine delivered through an IV (a drip into the arm) which is not currently FDA approved for use in the treatment of treatment-resistant depression (TRD) and Esketamine (Spravato®), taken as a nasal spray which has received FDA approval for use in the treatment of treatment-resistant depression (TRD) in the treatment of patients with treatment-resistant depression (TRD). The study will look a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Houston Center for Advanced Psychiatric Treatment, Bellaire, Texas
Conditions: Depression